Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept in Transfusion-dependent Beta-thalassemia (Southwest China)
NCT06164821Recruiting
- Sponsor
- Hematology Department, 920th Hospital
- Start
- Jan 2024
- Primary completion
- Jan 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Open-label, single-arm trial of luspatercept in beta thalassemia, sponsored by Hematology Department, 920th Hospital. Primary endpoints: Number of units in cumulative transfusion volume at 24 weeks and Proportion of patients with a 33% reduction in transfusion burden at 24 weeks. Started Jan 2024; status: recruiting.
02
Drugs
luspatercept
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT06164821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06164821.